Abstract
While Edwin Goldmann is recognized as the first to provide substantial evidence of a blood-brain barrier (BBB) in 1909 and 1913, the actual term was coined in 1900 by Max Lewandowsky after observing that central injection of sodium ferrocyanide produced seizures in dogs, while larger doses administered peripherally did not. In fact, the earliest clue to the existence of a separation between central nervous system (CNS) and peripheral tissue arose in 1885 from the studies of Paul Ehrlich, including those demonstrating that peripheral dye injection in rats failed to stain nervous tissue. However, these early observations by Ehrlich were attributed to differences in the capacity of dye uptake in CNS tissue. Later, Goldmann intravenously injected a dye, trypan blue, and similarly observed significant staining of all tissues, with the exception of the brain, spinal cord, eyes, peripheral nerves, and gonads. By subsequently showing trypan blue–stained CNS tissue after delivering the dye directly to cerebral spinal fluid (CSF), Goldmann negated theories that different tissue affinities for the dye accounted for lack of CNS staining after peripheral injection. Despite these important observations, the existence of a BBB remained a topic of debate for decades, until ensuing technological advances allowed progress. For example, the ability to visualize tissue ultrastructure using electron microscopy (EM) spurred studies into the cellular basis of the BBB. Notably, in 1967, Reese and Karnovsky analyzed electron micrographs of intravenous tracer-injected mouse brains, demonstrating that endothelial cells of cerebral capillaries act as a barrier between the blood and the brain and further defining characteristics of CNS versus peripheral capillary endothelial cells. Numerous advances have subsequently been made in our understanding of BBB structure, mechanisms, and development. Oldendorf et al. evidenced in 1977 that endothelial cells in the BBB region bear a higher amount of mitochondria (10%) that provides adenosine triphosphate (ATP) driving the ion gradients. In 1985, Combert and Stewart quantified the ultrastructure of the BBB and compared the CNS endothelial cells features to nonbarrier capillaries (e.g., somatic capillaries and area postrema). The wall thickness of the CNS endothelial cells is reduced around 40% in comparison with the area postrema offering exclusive properties to regulate molecules passage within the brain. More information about these developments can be found in Ribatti D, Nico B, Crivellato E, and Artico M (Anat Rec – Part B New Anat 289:3–8, 2006).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbott NJ, Rönnbäck L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41–53. https://doi.org/10.1038/nrn1824
Alli S, Figueiredo CA, Golbourn B et al (2018) Brainstem blood brain barrier disruption using focused ultrasound: a demonstration of feasibility and enhanced doxorubicin delivery. J Control Release 281:29–41. https://doi.org/10.1016/j.jconrel.2018.05.005
Bakay L, Hueter TF, Ballantine HT, Sosa D (1956) Ultrasonically produced changes in the blood-brain barrier. Arch Neurol Psychiatr 76:457–467. https://doi.org/10.1001/archneurpsyc.1956.02330290001001
Barar J, Rafi MA, Pourseif MM, Omidi Y (2016) Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts 6:225–248. https://doi.org/10.15171/bi.2016.30
Baskar R, Lee KA, Yeo R, Yeoh KW (2012) Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9:193–199. https://doi.org/10.7150/ijms.3635
Bellettato CM, Scarpa M (2018) Possible strategies to cross the blood–brain barrier. Ital J Pediatr 44:127–161. https://doi.org/10.1186/s13052-018-0563-0
Blackburn D, Sargsyan S, Monk PN, Shaw PJ (2009) Astrocyte function and role in motor neuron disease: a future therapeutic target? Glia 57:1251–1264. https://doi.org/10.1002/glia.20848
Bogdahn U, Hau P, Stockhammer G et al (2011) Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13:132–142. https://doi.org/10.1093/neuonc/noq142
Bruce JN, Fine RL, Canoll P et al (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69:1272–1279. https://doi.org/10.1227/NEU.0b013e3182233e24
Bruheim K, Guren MG, Skovlund E et al (2010) Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76:1005–1011. https://doi.org/10.1016/j.ijrobp.2009.03.010
Cabezas R, Ávila M, Gonzalez J et al (2014) Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Front Cell Neurosci 8:1–11. https://doi.org/10.3389/fncel.2014.00211
Carpentier A, Laigle-Donadey F, Zohar S et al (2006) Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent gliobastoma. Neuro Oncol 8:60–66. https://doi.org/10.1215/S1522851705000475
Carpentier A, Metellus P, Ursu R et al (2010) Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 12:401–408. https://doi.org/10.1093/neuonc/nop047
Chen KT, Wei KC, Liu HL (2019) Theranostic strategy of focused ultrasound induced blood-brain barrier opening for CNS disease treatment. Front Pharmacol 10. https://doi.org/10.3389/fphar.2019.00086
Choi JJ, Selert K, Gao Z et al (2011) Noninvasive and localized blood-brain barrier disruption using focused ultrasound can be achieved at short pulse lengths and low pulse repetition frequencies. J Cereb Blood Flow Metab 31:725–737. https://doi.org/10.1038/jcbfm.2010.155
D’Amico RS, Neira JA, Yun J et al (2020) Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model. J Neurosurg 133:614–623. https://doi.org/10.3171/2019.3.JNS1963
Debinski W, Tatter SB (2009) Convection-enhanced delivery for the treatment of brain tumors. Expert Rev 9:1519–1527. https://doi.org/10.1586/ern.09.99
Desjardins A, Gromeier M, Herndon JE et al (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150–161. https://doi.org/10.1056/nejmoa1716435
Etame AB, Diaz RJ, Smith CA et al (2008) Focused ultrasound disruption of the blood brain barrier: a new frontier for therapeutic delivery in molecular neuro-oncology. Neurosurg Focus 32:1–7. https://doi.org/10.3171/2011.10.FOCUS11252
Furdui CM (2014) Ionizing radiation: mechanisms and therapeutics. Antioxidants Redox Signal 21:218–220. https://doi.org/10.1089/ars.2014.5935
Guijarro-Muñoz I, Compte M, Álvarez-Cienfuegos A et al (2014) Lipopolysaccharide activates toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytes. J Biol Chem 289:2457–2468. https://doi.org/10.1074/jbc.M113.521161
Haseloff RF, Dithmer S, Winkler L et al (2015) Transmembrane proteins of the tight junctions at the blood-brain barrier: structural and functional aspects. Semin Cell Dev Biol 38:16–25. https://doi.org/10.1016/j.semcdb.2014.11.004
Hau P, Jachimczak P, Schlingensiepen R et al (2007) Inhibition of TGF-β2 with ap 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17:201–212. https://doi.org/10.1089/oli.2006.0053
Hiyama TY, Noda M (2016) Sodium sensing in the subfornical organ and body-fluid homeostasis. Neurosci Res 113:1–11. https://doi.org/10.1016/j.neures.2016.07.007
Hunt Bobo R, Laske DW, Akbasak A et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076–2080. https://doi.org/10.1073/pnas.91.6.2076
Iadecola C (2017) The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron 96:17–42. https://doi.org/10.1016/j.neuron.2017.07.030
Izadifar Z, Babyn P, Chapman D (2017) Mechanical and biological effects of ultrasound: a review of present knowledge. Ultrasound Med Biol 43:1085–1104. https://doi.org/10.1016/j.ultrasmedbio.2017.01.023
Jahangiri A, Chin AT, Flanigan PM et al (2017) Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg 126:191–200. https://doi.org/10.3171/2016.1.JNS151591
Jansson D, Rustenhoven J, Feng S et al (2015) A role for human brain pericytes in neuroinflammation. J Neuroinflammation 12:1–20. https://doi.org/10.1186/s12974-015-0430-5
Kaur C, Ling EA (2017) The circumventricular organs. Histol Histopathol 32:879–892. https://doi.org/10.14670/HH-11-881
Khamchai S, Chumboatong W, Hata J et al (2020) Morin protects the blood–brain barrier integrity against cerebral ischemia reperfusion through anti-inflammatory actions in rats. Sci Rep 10:1–13. https://doi.org/10.1038/s41598-020-70214-8
Kim H, Chiu A, Lee SD et al (2014) Focused ultrasound-mediated non-invasive brain stimulation: examination of sonication parameters. Brain Stimul 7:748–756. https://doi.org/10.1016/j.brs.2014.06.011
Kugelmann D, Rotkopf LT, Radeva MY et al (2018) Histamine causes endothelial barrier disruption via Ca2+−mediated RhoA activation and tension at adherens junctions. Sci Rep 8:1–14. https://doi.org/10.1038/s41598-018-31408-3
Kunvvar S (2003) Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88:105–111. https://doi.org/10.1007/978-3-7091-6090-9_16
Kunwar S, Chang SM, Prados MD et al (2006) Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20:1–15
Kunwar S, Prados MD, Chang SM et al (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the cintredekin besudotox intraparenchymal study group. J Clin Oncol 25:837–844. https://doi.org/10.1200/JCO.2006.08.1117
Kunwar S, Chang S, Westphal M et al (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12:871–881. https://doi.org/10.1093/neuonc/nop054
Langlet F, Mullier A, Bouret SG et al (2013) Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain. J Comp Neurol 521:3389–3405. https://doi.org/10.1002/cne.23355
Lapin NA, Gill K, Shah BR, Chopra R (2020) Consistent opening of the blood brain barrier using focused ultrasound with constant intravenous infusion of microbubble agent. Sci Rep 10:1–11. https://doi.org/10.1038/s41598-020-73312-9
Laske WD, Richard Y, Edward HO (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature 3:3–8. https://doi.org/10.1038/nm1297-1362
Lawrence YR, Li XA, el Naqa I et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76:20–27. https://doi.org/10.1016/j.ijrobp.2009.02.091
Li Q, Sui H, Fan ZZ (2012) Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res 40:426–435. https://doi.org/10.1177/147323001204000204
Lidar Z, Mardor Y, Jonas T et al (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472–479. https://doi.org/10.3171/jns.2004.100.3.0472
Lim JC, Kania KD, Wijesuriya H et al (2015) Activation of β -catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem 106:1855–1865. https://doi.org/10.1111/j.1471-4159.2008.05537
Liu S, Agalliu D, Yu C, Fisher M (2012) The role of pericytes in blood-brain barrier function and stroke. Curr Pharm Des 18:3653–3662. https://doi.org/10.2174/138161212802002706
Lu C, Diehl SA, Noubade R et al (2010) Endothelial histamine H1 receptor signaling reduces blood-brain barrier permeability and susceptibility to autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 107:18967–18972. https://doi.org/10.1073/pnas.1008816107
Meng Y, Suppiah S, Surendrakumar S et al (2018) Low-intensity MR-guided focused ultrasound mediated disruption of the blood-brain barrier for intracranial metastatic diseases. Front Oncol 8:1–8. https://doi.org/10.3389/fonc.2018.00338
Neuwelt EA, Bauer B, Fahlke C et al (2011) Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12:169–182. https://doi.org/10.1038/nrn2995
Obermeier B, Daneman R, Ransohoff RM (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19:1584–1596. https://doi.org/10.1038/nm.3407
Oldfield BJ, McKinley MJ (2015) Circumventricular organs. In: The rat nervous system, 4th edn. Academic, pp 315–333. https://doi.org/10.1016/B978-0-12-374245-2.00015-2
Ott D, Murgott J, Rafalzik S et al (2010) Neurons and glial cells of the rat organum vasculosum laminae terminalis directly respond to lipopolysaccharide and pyrogenic cytokines. Brain Res 1363:93–106. https://doi.org/10.1016/j.brainres.2010.09.083
Patel SJ, Shapiro WR, Laske DW et al (2005) Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:1243–1252. https://doi.org/10.1227/01.NEU.0000159649.71890.30
Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223–236. https://doi.org/10.1007/s11481-006-9025-3
Pöpperl G, Goldbrunner R, Gildehaus FJ et al (2005) O-(2-[18F]fluoroethyl)-l-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 32:1018–1025. https://doi.org/10.1007/s00259-005-1819-7
Price CJ, Hoyda TD, Ferguson AV (2008) The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist 14:182–194. https://doi.org/10.1177/1073858407311100
Qin D, Ma J, Xiao J, Tang Z (1997) Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol 20:263–265. https://doi.org/10.1097/00000421-199706000-00011
Rand RW, Kreitman RJ, Patronas N et al (2000) Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6:2157–2165
Rhea EM, Banks WA (2019) Role of the blood-brain barrier in central nervous system insulin resistance. Front Neurosci 13:1–14. https://doi.org/10.3389/fnins.2019.00521
Sampson JH, Akabani G, Archer GE et al (2003) Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain. J Neuro-Oncol 65:27–35. https://doi.org/10.1023/A:1026290315809
Sampson JH, Akabani G, Friedman AH et al (2006) Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 20:1–4. https://doi.org/10.3171/foc.2006.20.4.9
Sampson JH, Akabani G, Archer GE et al (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10:320–329. https://doi.org/10.1215/15228517-2008-012
Sarosiek KA, Fraser C, Muthalagu N et al (2017) Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell 31:142–156. https://doi.org/10.1016/j.ccell.2016.11.011
Shin J, Kong C, Cho JS et al (2018) Focused ultrasound-mediated noninvasive blood-brain barrier modulation: preclinical examination of efficacy and safety in various sonication parameters. Neurosurg Focus 44:1–10. https://doi.org/10.3171/2017.11.FOCUS17627
Souweidane MM, Kramer K, Pandit-Taskar N et al (2018) Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol 19:1040–1050. https://doi.org/10.1016/S1470-2045(18)30322-X
Tanner PG, Holtmannspötter M, Tonn J-C, Goldbrunner R (2007) Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery 61:E880–E882. https://doi.org/10.1227/01.NEU.0000280074.43962.2C
Thanabalasundaram G, Schneidewind J, Pieper C, Galla HJ (2011) The impact of pericytes on the blood-brain barrier integrity depends critically on the pericyte differentiation stage. Int J Biochem Cell Biol 43:1284–1293. https://doi.org/10.1016/j.biocel.2011.05.002
Tsai HC, Tsai CH, Chen WS et al (2018) Safety evaluation of frequent application of microbubble-enhanced focused ultrasound blood-brain-barrier opening. Sci Rep 8:1–13. https://doi.org/10.1038/s41598-018-35677-w
Van Dam F, Schagen S, Muller M et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. Cancer 90:210–218. https://doi.org/10.1093/jnci/90.3.210
Van Vulpen M, Kal HB, Taphoorn MJB, El Sharouni SY (2002) Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 9:683–688. https://doi.org/10.3892/or.9.4.683
Vogelbaum MA, Aghi MK (2015) Convection-enhanced delivery for the treatment of glioblastoma. Neuro Oncol 17:ii3–ii8. https://doi.org/10.1093/neuonc/nou354
Vogelbaum MA, Sampson JH, Kunwar S et al (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61:1031–1038. https://doi.org/10.1152/ajplegacy.1933.107.1.76
Voges J, Reszka R, Gossmann A et al (2003) Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54:479–487. https://doi.org/10.1002/ana.10688
Weaver M, Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65:3–13. https://doi.org/10.1023/a:1026246500788
Weber F, Asher A, Bucholz R et al (2003a) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neuro-Oncol 64:125–137. https://doi.org/10.1023/A:1024901501173
Weber FW, Floeth F, Asher A et al (2003b) Local convection enhanced delivery of IL4-pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. BMC Public Health 88:93–103. https://doi.org/10.1007/978-3-7091-6090-9_15
Yoo HJ, Kim H, Park HJ et al (2016) Neurocognitive function and health-related quality of life in pediatric Korean survivors of medulloblastoma. J Korean Med Sci 31:1726–1734. https://doi.org/10.3346/jkms.2016.31.11.1726
Zeevi N, Pachter J, McCullough LD et al (2010) The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc 58:1749–1757. https://doi.org/10.1111/j.1532-5415.2010.03011.x
Zeng YD, Liao H, Qin T et al (2015) Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget 6:8366–8376. https://doi.org/10.18632/oncotarget.3187
Zhang T, Su J, Guo B et al (2015) Apigenin protects blood-brain barrier and ameliorates early brain injury by inhibiting TLR4-mediated inflammatory pathway in subarachnoid hemorrhage rats. Int Immunopharmacol 28:79–87. https://doi.org/10.1016/j.intimp.2015.05.024
Zhao B, Chen Y, Liu J et al (2018) Blood-brain barrier disruption induced by diagnostic ultrasound combined with microbubbles in mice. Oncotarget 9:4897–4914. https://doi.org/10.18632/oncotarget.23527
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Science+Business Media, LLC, part of Springer Nature
About this entry
Cite this entry
Martin, B., Leshan, R., Milner, T.A., Souweidane, M. (2022). Blood-Brain Barrier. In: Pfaff, D.W., Volkow, N.D., Rubenstein, J.L. (eds) Neuroscience in the 21st Century. Springer, Cham. https://doi.org/10.1007/978-3-030-88832-9_129
Download citation
DOI: https://doi.org/10.1007/978-3-030-88832-9_129
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-88831-2
Online ISBN: 978-3-030-88832-9
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences